Sector News

CVC Capital revs up rare disease ambitions with $3.5B Recordati buyout

July 3, 2018
Life sciences

Recordati has finally sealed a sale. Private equity player CVC Capital Partners said Friday it would drop €3.03 billion—€2.3 billion in cash and €750 million in long-term debt—to pick up the Recordati family’s 51.8% controlling stake in the company.

The agreement follows a Financial Times report that squabbling among members of the Recordati family—who have been weighing a sale since the 2016 death of CEO Giovanni Recordati—might have scuttled a potential deal. Political uncertainty in Italy also gave CVC pause at one point, the FT noted.

Now, though, Recordati has a “great outcome” on its hands, CEO Andrea Recordati—who will stay on as skipper after the deal closes—said in a statement.

“It was important to find a party that would allow Recordati to remain independent, with continuity for management and employees, and accelerate its growth strategy as a leading global consolidator in the pharmaceutical industry,” he said in a statement, adding that he was “personally reinvesting … as I believe in and support Recordati.”

CVC, for its part, is hoping it can expand Recordati’s “very attractive rare disease business” alongside the company’s core business, Cathrin Petty, CVC’s head of EMEA healthcare, said in her own statement.

“We hope that through our expertise and global healthcare network we will help accelerate this growth across orphan and specialty care to build a global leader in the industry,” she said. CVC’s portfolio currently includes Italian generics maker DOC Generici, as well as copycat Alvogen.

Before landing on CVC as a deal partner, Recordati held informal talks with Asian bidders, and private equity firms Bain and Cinven also reportedly took a look at the company. Before selling, though, Recordi put on its buyer’s hat, forking over $300 million to AstraZeneca in exchange for European rights to heart drug Seloken and related combo product Logimax.

By Carly Helfand

Source: Fierce Pharma

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend